NATCO Pharma Limited (NATCOPHARM) Earnings Call Transcripts

NATCO Pharma Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, NATCO Pharma reported consolidated total revenue of INR 4,375.9 crores, down from INR 4,784 crores year-over-year, reflecting a challenging market environment. The net profit for the quarter was INR 268 crores, significantly lower than INR 406 crores in the same quarter last year, influenced by a one-time tax benefit of INR 115 crores. Management guided for FY '27 revenue expectations between INR 3,400 to INR 3,500 crores and net profit between INR 700 to INR 750 crores, indicating a cautious outlook for the upcoming fiscal year.

Reported metrics

Guidance from management

Management expects FY '27 revenue to be between INR 3,400 to INR 3,500 crores and net profit between INR 700 to INR 750 crores, indicating a cautious outlook for the upcoming fiscal year.

What management said

I think as you point of this impact of revenue less regard the decline. The second question was if we have an impact of Middle is we were able to supply our products. We had some things that we were able to supply. But there has been an increase in the price expenses because we had to reroute from a traditional carriers, but we were able to manage .

Yes. So yes, the other expenses largely this quarter, we had higher R&D expenses. And also during the quarter, we had looked some of the inertia there were some write-down -- so net, it is largely because of engines and reiterate because of the engineering expense rate.

What analysts pressed on

Analysts expressed concerns over the significant decline in revenue and profit, questioning the sustainability of earnings and the impact of increased R&D expenses on future profitability. There were also inquiries about the company's strategic direction amidst a challenging market environment.

Main topics on the call

• Revenue Decline — NATCO's total revenue for FY '26 decreased to INR 4,375.9 crores from INR 4,784 crores in the previous year. Management noted, "the impact of revenue less regard the decline," highlighting the challenging market conditio...
• Profitability Challenges — The net profit for Q4 FY '26 was INR 268 crores, down from INR 406 crores year-over-year. Management acknowledged that the profit included a one-time tax benefit, stating, "the net profit for the quarter includes a one-t...
• Guidance for FY '27 — Management provided revenue guidance of INR 3,400 to INR 3,500 crores for FY '27, with net profit expected between INR 700 to INR 750 crores. They noted, "there's some buffer, but I think that's our expectation that we d...
• Increased R&D Expenses — Management indicated that R&D expenses increased significantly due to ongoing projects, with expectations to spend about 7% to 9% of revenue on R&D in FY '27. They mentioned, "we had higher R&D expenses" during the quart...

Read the full NATCO Pharma Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 24 NATCO Pharma Limited earnings call transcripts on record, spanning February 13, 2020 to May 29, 2026. Based on this history, NATCO Pharma Limited reports quarterly. The most recent call on file is dated May 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

NATCOPHARM

Exchange

NSEI

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

24

First call

February 13, 2020

Most recent

May 29, 2026

Reporting cadence

quarterly